

April 07, 2022

Lincoln Pharmaceuticals Ltd.: Ratings reaffirmed

Summary of rating action

Instrument*	Previous Rated Amount (Rs. crore)	Current Rated Amount (Rs. crore)	Rating Action
Long-term– Fund-based Limit	48.00	45.00	[ICRA]A(Stable); Reaffirmed
Long-term– Interchangeable Limit	(30.00)	(15.00)	[ICRA]A(Stable); Reaffirmed
Long-term–Unallocated Limit	5.00	3.00	[ICRA]A(Stable); Reaffirmed
Short -term – Non-Fund based	12.00	17.00	[ICRA]A1; Reaffirmed
Total	65.00	65.00	

*Instrument details are provided in Annexure-1

Rationale

The rating reaffirmation of Lincoln Pharmaceutical Limited (LPL) continues to consider the extensive track record of the promoters in the pharmaceutical formulations business along with its established relationships with customers, which has entailed repeat orders. The ratings also continue to draw comfort from the company's diversified product profile catering to several therapeutic areas, coupled with its growing geographical footprint across India and surging share of exports to unregulated and semi-regulated markets. The ratings continue to favourably take into account the company's comfortable capital structure aided by low reliance on external debt and the subsequent healthy coverage indicators, along with a sound liquidity profile backed by sizable cash and liquid investment with unutilised working capital limits.

The ratings, however, remain constrained by the susceptibility of LPL's profitability to movements in prices of active pharmaceutical ingredients (APIs; raw materials) and changes in Government policies mainly related to price control. Further, the risk is accentuated given its considerable product offering falling under the ambit of drug price control order (DPCO) by the regulators under the Essential Commodities Act, which limits pricing flexibility. Further, the intense competition in the domestic generic formulations industry with both organised and unorganised players continues to keep revenues and margin under check. The ratings also remain constrained by the high working capital intensity of operations, owing to the long credit period extended to its customers, especially in export markets. ICRA also notes that the company has extended sizable inter-corporate loans to unrelated parties, hence, their timely recovery will be critical from a liquidity as well as overall credit perspective and will remain a key rating monitorable.

The Stable outlook reflects ICRA's opinion that the LPL revenue profile will be backed by stable demand conditions, along with limited debt levels, given that no large debt-funded capital expenditure (capex) is envisaged, thereby maintaining its credit metrics in the near term.

Key rating drivers and their description

Credit strengths

Extensive experience of promoters and established customer relationships – The promoters have extensive experience of more than three decades in the pharmaceutical formulation business. Over the period, the LPL has developed established relationships with its customers, which has entailed repeat orders.

Diversified product profile catering to multiple therapeutic areas and expanding geographical presence – LPL manufactures pharmaceutical formulations in various forms such as tablets, capsules, ointments, syrups, dry powder and liquid injections. At present, the product portfolio remains diversified with more than 500 formulations, catering to various therapeutic segments such as antibiotics, analgesics, anti-cold drugs, gynaecology, anti-malarial, and multi-vitamins. LPL was predominately a domestic market player; however, it has been increasing its focus on exports to semi-regulated markets in the past few fiscals, owing to intense competition in the domestic generic formulation's industry. The export sales are concentrated, with African markets generating ~32-35% to the total export sales, while the company has a diversified presence in the domestic market in more than 20 states.

Also, on October 2021, LPL has received an approval from Australia's medicines and medical devices regulator, Therapeutic Goods Administration (TGA). The certification will be valid till June 2023. The company's manufacturing facility in Khatraj, Gujarat, received the clearance from TGA for all three departments—tablets, capsules and cream, and ointments—which will cover a wide range of its pharmaceutical formulations. Also, in the near term, LPL is planning to enter the Australian market with its dermatology, gastro and pain management products and gradually expand its product portfolio.

Comfortable capital structure and healthy debt protection metrics – Given the presence of minimal debt as on March 31, 2021, LPL's capital structure remains comfortable along with subsequent robust interest coverage of 55.93 times, total Debt/OPBDITA of 0.01 time and TOL/TNW of 0.22 time as on March 31, 2021. LPL's reliance on external debt continues to remain controlled leading to favourable capital structure and sound debt protection metrics.

Healthy cash and liquid investments along with sparsely utilised working capital limits – LPL maintains a sound liquidity profile supported by sizable cash and liquid funds to the tune of Rs. 94.3 crore as on March 21, 2021, along with sparsely utilised working capital limits

Credit challenges

Moderate scale of operations amid intense competition in generic formulations industry – LPL remains a mid-sized player in the generic formulations industry with an operating income of Rs. 424.2 crore in FY2021 at the consolidated level. For the nine months ending December 2021, the sales stood at Rs. 369.5 crore (consolidated). The domestic generic formulation industry faces stiff competition from numerous contract manufacturers, multi-national companies as well as established domestic brands, with some of these players also having a pan India presence. The intense competition in the industry keeps revenue growth and margins under check. However, in H1 FY2022, the company has acquired a plant in Mehsana (Gujarat) and plans to launch Cephalosporin products at the facility. The operation in the said plant will commence from April 2022 onwards which will aid to near term revenue growth and earnings.

Operations exposed to regulatory restrictions; considerable coverage under DPCO, which restricts pricing flexibility - The operations remain exposed to regulatory restrictions in terms of pricing caps in domestic markets and product/facility approvals in export destinations. Amid escalating raw material prices coupled with considerable product offering falling under the ambit of DPCO by the regulators under the Essential Commodities Act, which limits pricing flexibility. However, the impact of DPCO restricted pricing are severe in the initial year, later an annual price revision at regulator determined rates are allowed which provides some respite in the pricing flexibility. Going forward, with increasing focus on exports, ICRA notes that timely product and facility approval/renewal in various semi-regulated markets remains critical for the growth of exports.

Sizable amount lent as inter-corporate loan to individuals and entities, timely recovery of the same remains critical from credit perspective – LPL has extended sizable inter-corporate loans to unrelated parties, which stood at ~Rs. 44 crore as on March 31, 2021. Their timely recovery will be critical from a liquidity profile as well as overall credit perspective and, hence, will remain a key rating monitorable, going forward.

High working capital intensity of operations – The working capital intensity of LPL remains relatively high as depicted by NWC/OI of 40% in FY2021 owing to sizable share of its exports market, which has a higher credit period (up to ~120 days over ~60-90 days in the domestic market), coupled with moderate inventory requirement.

Liquidity position: Strong

At a consolidated level, the liquidity position of LPL is strong, supported by healthy cash accruals of ~Rs. 67.15 crore in FY2021 along with free cash/liquid investments of Rs. 94.3 crore as on March 31, 2021. Further, there was no term debt outstanding as on December 31, 2021. The liquidity is also supported by cushion in working capital limits given the limited utilisation levels in the last 12 months.

Rating sensitivities

Positive factors – ICRA could upgrade the ratings if LPL demonstrates healthy scaling up of operations, while improving its profitability and working capital cycle.

Negative factors – Negative pressure on LPL's ratings could arise if a substantial decline in the scale of operations and profitability results in material deterioration of coverage indicators; or a sizeable capex or increase in working capital cycle adversely impacts the liquidity profile and key credit metrics.

Analytical approach

Analytical Approach	Comments
Applicable Rating Methodologies	Corporate Credit Rating Methodology Rating Methodology for entities in the Pharmaceutical Industry Consolidation and Rating Approach
Parent/Group Support	Not applicable
Consolidation/Standalone	Consolidation For arriving at the ratings, ICRA has combined the business and financial risk profiles of LPL and its wholly owned subsidiary, Zullinc Healthcare LLP, as the entity is owned and managed by the same promoters and is involved in related business segments.

About the company

Established as a partnership firm in 1979, Lincoln Pharmaceuticals Limited has been manufacturing pharmaceutical formulations in the domestic market as well as exporting formulations. LPL was reconstituted as a public limited company in 1995 and is listed on the BSE. Its manufacturing plant, at Kharjat in Gandhinagar district of Gujarat, has an installed manufacturing capacity of 200-crore tablets, 45-crore capsules, and 90-lakh packs of ointments per annum. The unit is ISO 9001, ISO 14001 and OHSAS 18001 certified and EUGMP, WHO, cGMP, MHRA and TGA compliant¹. In H1 FY2022, the company has acquired a plant in Mehsana (Gujarat) and plans to launch Cephalosporin products at the facility.

The company is a part of the Lincoln Group, which manufactures pharmaceuticals formulations in categories such as generics, anti-malarial, anti-diabetic, gynaecology products, vitamins, minerals and anti-oxidants. LPL's erstwhile subsidiary (98.58% holding) Lincoln Parenteral Limited (LPPL), incorporated in 1991, was involved in manufacturing formulations in dry powder, liquid injectables and syrup variants. On September 14, 2021, the Hon'ble National Company Law Tribunal, Ahmedabad Bench (NCLT), approved the scheme of amalgamation of Lincoln Parenteral Ltd and Lincoln Pharmaceuticals Ltd. The amalgamation is likely to weed out duplications in activities and costs and shall enhance the easy of management.

Currently, LPL has a wholly-owned subsidiary, Zullinc Healthcare Limited, which trades and markets pharmaceutical products.

¹ OHSAS: Occupational Health and Safety Management System; MHRA: Medicines and Healthcare products; Regulatory Agency; TGA: Therapeutic Goods Administration

Key financial indicators

	Consolidated		
	FY2020	FY2021	9M FY2022
Operating Income (Rs. crore)	386.49	424.19	369.54
PAT (Rs. crore)	51.47	62.25	58.33
OPBDIT/OI (%)	17.11%	20.60%	21.12%
PAT/OI (%)	13.32%	14.68%	15.79%
Total Outside Liabilities/Tangible Net Worth (times)	0.24	0.22	-
Total Debt/OPBDIT (times)	0.08	0.01	-
Interest Coverage (times)	32.77	55.93	87.68

PAT: Profit after Tax; OPBDIT: Operating Profit before Depreciation, Interest, Taxes and Amortisation

Status of non-cooperation with previous CRA: Not applicable

Any other information: None

Rating history for past three years

	Instrument	Current Rating (FY2023)				Chronology of Rating History for the past 3 years		
		Type	Amount Rated (Rs. crore)	Amount Outstanding (Rs. crore)	Date & Rating in	Date & Rating in FY2022	Date & Rating in FY2021	Date & Rating in FY2020
					Apr 07, 2022	-	Feb 11, 2021	Dec 26, 2019
1	Export Packing Credit	Long-term	45.00	-	[ICRA]A(Stable)	-	[ICRA]A(Stable)	[ICRA]A- (Positive)
3	Fund based working capital Sublimit - CC	Long-term	(15.00)	-	[ICRA]A(Stable)	-	[ICRA]A(Stable)	[ICRA]A- (Positive)
4	Unallocated Limits	Long-term	3.00	-	[ICRA]A(Stable)	-	[ICRA]A(Stable)	[ICRA]A- (Positive)
5	Letter of Credit (LC)	Short-term	6.00	-	[ICRA]A1	-	[ICRA]A1	[ICRA]A2+
6	Bank Guarantee (BG)	Short-term	6.00		[ICRA]A1	-	[ICRA]A1	[ICRA]A2+
7	LC/BG	Short-term	5.00		[ICRA]A1	-	[ICRA]A1	[ICRA]A2+

Complexity level of the rated instruments

Instrument	Complexity Indicator
Cash Credit	Simple
Interchangeable Limit	Simple
Unallocated Limits	NA
Letter of Credit (LC)	Very Simple
Bank Guarantee (BG)	Very Simple
LC/BG	Very Simple

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or

complexity related to the structural, transactional, or legal aspects. Details on the complexity levels of the instruments, is available on ICRA's website: www.icra.in

Annexure-1: Instrument details

ISIN No.	Instrument Name	Date of Issuance	Coupon Rate	Maturity	Amount Rated (RS Crore)	Current Rating and Outlook
NA	EPC	NA	NA	NA	45.00	[ICRA]A(Stable)
NA	Interchangeable Limit - CC	NA	NA	NA	(15.00)	[ICRA]A(Stable)
NA	Unallocated Limits	NA	NA	NA	3.00	[ICRA]A(Stable)
NA	Letter of Credit (LC)	NA	NA	NA	6.00	[ICRA]A1
NA	Bank Guarantee (BG)	NA	NA	NA	6.00	[ICRA]A1
NA	LC/BG	NA	NA	NA	5.00	[ICRA]A1

Source: Company

Annexure-2: List of entities considered for consolidated analysis

Company Name	Ownership	Consolidation Approach
Lincoln Pharmaceuticals Limited	100.00%	Full Consolidation
Zullinc Healthcare LLP	100.00%	Full Consolidation

ANALYST CONTACTS

Shamsher Dewan
+91 9560555399
shamsherd@icraindia.com

Srikumar Krishnamurthy
+91 9884086366
ksrikumar@icraindia.com

Suprio Banerjee
+91 9820244979
supriob@icraindia.com

Srinivas Menon
+91 9167322924
srinivas.menon2@icraindia.com

RELATIONSHIP CONTACT

Jayanta Chatterjee
+91 80 4332 6401
jayantac@icraindia.com

MEDIA AND PUBLIC RELATIONS CONTACT

Ms. Naznin Prodhani
Tel: +91 124 4545 860
communications@icraindia.com

Helpline for business queries

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)
info@icraindia.com

About ICRA Limited:

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in

ICRA Limited



Registered Office

B-710, Statesman House, 148, Barakhamba Road, New Delhi-110001
Tel: +91 11 23357940-45



Branches



© Copyright, 2022 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents.